Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonrotoclax ramp-up safety study in CLL and mantle cell lymphoma
2024-518829-15-00Phase 2Authorised
- Sponsor
- BeOne Medicines
- Start
- Jul 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label trial of sonrotoclax and zanubrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL) (2 arms), sponsored by BeOne Medicines. Primary endpoint: Incidence and severity of tumor lysis syndrome. Planned start Jul 2025; status: authorised.
02
Drugs
sonrotoclaxzanubrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2024-518829-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518829-15-00.